Yourgene Health PLC COVID-19 Surge testing contract
RNS Number : 2020J
Yourgene Health PLC
19 August 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Yourgene's COVID-19 testing investment reaps rewards
DHSC contract secured to support COVID-19 surge testing
Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading
international molecular diagnostic group, confirms that Yourgene
Genomic Services ('YGS') has been awarded a contract for provision
of laboratory capacity to the NHS Test and Trace Programme for
COVID-19 testing by the Department of Health & Social Care
In April 2021, the Company announced it was successful in
securing tenders under Public Health England's National
Microbiology Framework for Lots 1-4 and was one of only three
companies to successfully be awarded all four Lots. This meant
public health authorities across the UK were able to issue call-off
contracts to procure goods and testing services from Yourgene.
This contract is the first to come of the National Microbiology
Framework Lot wins announced earlier this year, using Yourgene's
high throughput automated COVID-19 services testing laboratory in
Citylabs 1.0, Manchester. The final contract notice value is the
maximum estimated value of the contract. Actual value will depend
on services purchased. There is no committed spend.
Lyn Rees, Chief Executive Officer, commented: "We are delighted
to have been awarded this first contract from the framework,
supporting the Government's testing needs utilising our recently
completed high throughput COVID-19 diagnostic testing
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation. The Directors of the Company
take responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer email@example.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Nicholas Moore / Matthew Blawat / Ben
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or firstname.lastname@example.org
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health plc
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genomic services and
technologies. The group works in partnership with global leaders in
DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and infectious diseases.
The Group's flagship in vitro diagnostic products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other
genetic disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests and DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation
platforms, powered by Ranger(R) Technology, the Yourgene
LightBench(R) and Yourgene QS250, ideal for cell-free DNA
applications in NIPT and oncology including liquid biopsy.
Yourgene Genomic Services is a global laboratory service network
equipped to be a full life-cycle partner for clinical, research and
pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop,
manufacture, obtain regulatory approval and commercialise new
products and services. In addition, Yourgene Genomic Services
offers an NIPT and high throughput COVID testing service.
Yourgene Health is headquartered in Manchester, UK with
facilities in Taipei, Singapore, the US and Canada, and is listed
on the London Stock Exchange's AIM market under the ticker "YGEN".
Follow us on LinkedIn and Twitter .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
August 19, 2021 07:04 ET (11:04 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2022 to May 2022
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2021 to May 2022